DP
QTTB icon

Diadema Partners’s Q32 Bio QTTB Stock Holding History

Diadema Partners’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,100
Closed -$121K – 160
2024
Q4 		$121K Buy
+35,100
New +$1.11M 0.05% 91

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Diadema Partners's QTTB Position: Q1 2025 in Review

Diadema Partners sold out of Q32 Bio (QTTB) in Q1 2025, closing a stake of 19,700 shares — an estimated $67.8K sold.

Diadema Partners first reported a position in QTTB in Q4 2024 and held it in 1 quarter. The position peaked at $67.8K in Q4 2024. 73 funds tracked by Wall St. Rank hold QTTB as of Q1 2025.

  • Diadema Partners reported no remaining Q32 Bio position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 19,700 Q32 Bio shares in Q1 2025, an estimated $67.8K.
  • Diadema Partners first reported a position in Q32 Bio in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's Q32 Bio position peaked at $67.8K in Q4 2024.
  • 73 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.